Physician profile
Rodney Morillo
NPI 1891096368
$6,097.08
in general payments reported to CMS, 2019-2025
40 companies · $907 in 2025
The $907 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,248 · 2022: $1,550 · 2023: $1,300 · 2024: $1,091 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,298.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,350.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Antares Pharma, INC. | $826.00 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Lilly USA, LLC | $542.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $510.18 | 2021-2025 | |
| Noven Therapeutics, LLC | $266.93 | 2024-2025 | Xelstrym |
| Pfizer INC. | $239.37 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $212.87 | 2021 | |
| Ibsa Pharma INC. | $193.79 | 2021-2025 | Tirosint, Licart, Licart |
| Teva Pharmaceuticals USA, INC. | $154.99 | 2021-2024 | Ajovy |
| Acella Pharmaceuticals, LLC | $149.15 | 2022-2025 | NP Thyroid 60 |
| Amgen INC. | $147.63 | 2021-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $139.77 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $117.05 | 2023-2025 | Veozah |
| Eisai INC. | $114.76 | 2021-2022 | |
| Halozyme INC | $111.87 | 2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Morillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.